IDEXX Laboratories stock (US45168D1046): Shares drop 4.7% to $533.92

IDEXX Laboratories stock fell 4.7% on May 12, 2026, to $533.92, reflecting ongoing challenges in the year, GuruFocus as of May 12, 2026. The Nasdaq-listed company, known for animal health diagnostics, has seen monthly declines of around 5.91% through May 2026, StockTitan as of May 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

IDEXX Laboratories: core business model

IDEXX Laboratories develops and distributes products for companion animal and livestock health. The company focuses on diagnostic instruments, tests, and software for veterinarians worldwide. Its portfolio includes point-of-care analyzers and cloud-based practice management tools, serving over 175 countries. IDEXX generates the bulk of revenue from the U.S. market, making it relevant for American investors tracking healthcare innovation.

Main revenue and product drivers for IDEXX Laboratories

Companion animal group accounts for over 75% of sales, driven by IDEXX SNAP tests and ProCyte hematology analyzers. Livestock, poultry, and dairy segments contribute through water testing and pathogen detection kits. In Q4 2024 results published February 2025, revenue reached $1.055 billion, up 9% organically, per company filings. Reference lab services and consumables provide recurring revenue, bolstering stability amid stock volatility.

Industry trends and competitive position

The veterinary diagnostics market grows at 8-10% annually, fueled by pet ownership in the U.S. and rising wellness spending. IDEXX holds about 40% market share in key segments, ahead of rivals like Zoetis. Advances in molecular diagnostics position it well, though competition intensifies from startups in AI-driven vet tech.

Why IDEXX Laboratories matters for US investors

Listed on Nasdaq, IDEXX benefits from strong U.S. pet industry exposure, where 70% of households own pets. Its innovation in diagnostics aligns with healthcare trends, offering growth potential tied to American consumer spending on animal care.

Conclusion

The recent 4.7% drop in IDEXX Laboratories stock highlights short-term pressures, yet its dominant position in veterinary diagnostics supports long-term relevance. Investors monitor upcoming earnings for recovery signals. Market dynamics remain key.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.